한글목차

천식 및 COPD 치료제 동향 및 전망

세계 천식 및 COPD 치료제 시장은 2024년부터 2030년까지 4.3%의 연평균 복합 성장률(CAGR)로 2030년까지 약 408억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 호흡기 질환 치료법의 개선과 신제품 도입, 표적 약물 및 생물학적 제제에 대한 관심 증가, 그리고 도시화와 고령화 추세입니다. 세계 천식 및 COPD 치료제 시장의 미래는 천식 및 COPD 시장의 기회로 인해 유망합니다.

천식 및 COPD 치료제 시장 인사이트

Lucintel의 예측에 따르면, 예측 기간 동안 배합제는 가장 큰 부문으로 남을 것입니다.

북미는 천식 발병률 증가, 제조업의 중요한 주체들, 담배 흡연 습관, 그리고 이 지역의 탄탄한 인프라로 인해 예측 기간 동안 가장 규모가 큰 지역으로 남을 것입니다.

자주 묻는 질문

Q1. 시장 규모는?

A1. 세계 천식 및 COPD 치료제 시장은 2030년까지 약 408억 달러에 달할 것으로 예상됩니다.

Q2. 시장 성장 전망은?

A2. 세계 천식 및 COPD 치료제 시장은 2024년부터 2030년까지 연평균 4.3%의 성장률을 보일 것으로 예상됩니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은 무엇인가?

A3.이 시장의 주요 촉진요인은 호흡기 질환 치료법의 개선과 신제품 도입, 표적 의약품 및 생물학적 제제에 대한 관심 증가, 그리고 도시화와 고령화 진행입니다.

Q4. 시장의 주요 부문은?

A4. 세계 천식 및 COPD 치료제 시장의 미래는 천식 및 COPD 시장에 기회가 있고 유망합니다.

Q5. 시장의 주요 기업은?

A5. 주요 천식 및 COPD 치료제 기업은 다음과 같습니다.

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Q6. 향후 가장 큰 시장 부문은?

A6.Lucintel은 예측 기간 동안 배합제가 가장 큰 부문으로 남을 것으로 예상하고 있습니다.

Q7. 향후 5년간 가장 큰 시장으로 성장할 것으로 예상되는 지역은?

A7. 북미는 천식 빈도 증가, 제조업의 중요한 행위자의 존재, 담배 흡연 습관, 이 지역의 확립된 인프라로 인해 예측 기간 동안 가장 규모가 큰 지역으로 남을 것입니다.

Q8. 보고서 커스터마이징이 가능한가?

A8. 네. Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 천식 및 COPD 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 천식 및 COPD 치료제 시장 동향(2018-2023년)과 예측(2024-2030년)
• 질환별 세계의 천식 및 COPD 치료제 시장
  • 천식
  • COPD
• 의약품 클래스별 세계의 천식 및 COPD 치료제 시장
  • 배합제
  • 단시간 작용성 β2 자극제
  • 장시간 작용성 β2 자극제
  • 류코트리엔 길항제
  • 항콜린제
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 세계의 천식 및 COPD 치료제 시장
• 북미의 천식 및 COPD 치료제 시장
• 유럽의 천식 및 COPD 치료제 시장
• 아시아태평양의 천식 및 COPD 치료제 시장
• 기타 지역의 천식 및 COPD 치료제 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 질환별 세계의 천식 및 COPD 치료제 시장 성장 기회
  • 의약품 클래스별 세계의 천식 및 COPD 치료제 시장 성장 기회
  • 지역별 세계의 천식 및 COPD 치료제 시장 성장 기회
• 세계 천식 및 COPD 치료제 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 천식 및 COPD 치료제 시장 능력 확대
  • 세계 천식 및 COPD 치료제 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 유력 기업 개요

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

영문목차

Asthma and COPD Drugs Trends and Forecast

The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets. The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030 with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

A more than 150-page report is developed to help in your business decisions.

Asthma and COPD Drugs by Segment

The study includes a forecast for the global asthma and COPD drugs by diseases, medication class, and region.

Asthma and COPD Drugs Market by Diseases [Shipment Analysis by Value from 2018 to 2030]:

• Asthma
• COPD

Asthma and COPD Drugs Market by Medication Class [Shipment Analysis by Value from 2018 to 2030]:

• Combination Drugs
• Short Acting Beta Agonists
• Long Acting Beta Agonists
• Leukotriene Antagonists
• Anticholinergics
• Others

Asthma and COPD Drugs Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Asthma and COPD Drugs Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies asthma and COPD drugs companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the asthma and COPD drugs companies profiled in this report include-

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Asthma and COPD Drugs Market Insights

Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Features of the Global Asthma and COPD Drugs Market

Market Size Estimates: Asthma and COPD drugs market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Asthma and COPD drugs market size by diseases, medication class, and region in terms of value ($B).

Regional Analysis: Asthma and COPD drugs market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, medication class, and regions for the asthma and COPD drugs market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the asthma and COPD drugs market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the asthma and COPD drugs market size?

Answer: The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030.

Q2. What is the growth forecast for asthma and COPD drugs market?

Answer: The global asthma and COPD drugs market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the asthma and COPD drugs market?

Answer: The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

Q4. What are the major segments for asthma and COPD drugs market?

Answer: The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets.

Q5. Who are the key asthma and COPD drugs market companies?

Answer: Some of the key asthma and COPD drugs companies are as follows.

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Q6. Which asthma and COPD drugs market segment will be the largest in future?

Answer: Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

Q7. In asthma and COPD drugs market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the asthma and COPD drugs market by diseases (asthma and COPD), medication class (combination drugs, short acting beta agonists, long acting beta agonists, leukotriene antagonists, anticholinergics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Asthma and COPD Drugs Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Asthma and COPD Drugs Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Asthma and COPD Drugs Market by Diseases
  • 3.3.1: Asthma
  • 3.3.2: COPD
• 3.4: Global Asthma and COPD Drugs Market by Medication Class
  • 3.4.1: Combination Drugs
  • 3.4.2: Short Acting Beta Agonists
  • 3.4.3: Long Acting Beta Agonists
  • 3.4.4: Leukotriene Antagonists
  • 3.4.5: Anticholinergics
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Asthma and COPD Drugs Market by Region
• 4.2: North American Asthma and COPD Drugs Market
  • 4.2.2: North American Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.3: European Asthma and COPD Drugs Market
  • 4.3.1: European Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.3.2: European Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.4: APAC Asthma and COPD Drugs Market
  • 4.4.1: APAC Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.4.2: APAC Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.5: ROW Asthma and COPD Drugs Market
  • 4.5.1: ROW Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.5.2: ROW Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Asthma and COPD Drugs Market by Diseases
  • 6.1.2: Growth Opportunities for the Global Asthma and COPD Drugs Market by Medication Class
  • 6.1.3: Growth Opportunities for the Global Asthma and COPD Drugs Market by Region
• 6.2: Emerging Trends in the Global Asthma and COPD Drugs Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Asthma and COPD Drugs Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Asthma and COPD Drugs Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: Glaxosmithkline
• 7.3: Organon
• 7.4: Boehringer Ingelheim International
• 7.5: Abbott Laboratories
• 7.6: AstraZeneca
• 7.7: Sanofi
• 7.8: Hoffmann-La Roche
• 7.9: Vectura Group
• 7.10: Teva Pharmaceutical Industries